Otsuka Pharmaceutical
 | |
Native name |
大塚製薬株式会社 |
|---|---|
Romanized name |
Ōtsuka Seiyaku Kabushiki-gaisha |
| Type | Public KK |
|
TYO: 4578 TOPIX 100 Component |
|
| Industry | Pharmaceutical |
| Founded | 1921 (Originally founded), 1964 (Current corporation) |
| Founder | Busaburo Otsuka |
| Headquarters | , |
Number of locations |
69 |
Area served |
Worldwide |
Key people |
Tatsuo Higuchi (President) |
| Revenue | ¥ 1.74 trillion (2022) |
| ¥ 150.32 billion (2022) | |
| Owner |
Nomura Trust and Banking investment trusts (11.43%) and investment trusts managed by other banks |
Number of employees |
5,634 (2017) |
| Parent | Otsuka Holdings Co. Ltd |
| Website | otsuka.com |
Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社, Ōtsuka Seiyaku Kabushiki-gaisha) (TYO: 4578), abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.
History
OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an initial public offering (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader Takeda Pharmaceutical Company. The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.
Otsuka Pharmaceutical Co. Ltd Holdings
In 1955, the company started a football club called "Otsuka Pharmaceutical SC." In 2005 the name changed to Tokushima Vortis. The club is based in Naruto.
In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of CG Roxane.
In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology". This decision necessitated a revision in the terms of an agreement with UCB to end collaboration on immunology products while continuing collaboration in the CNS area.
In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready ADHD drug centanafadine (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.
In August 2023, the company announced its intention to acquire Mindset Pharma Inc for up to CAD$80 million.
Acquisition history
-
Otsuka Pharmaceutical Co., Ltd
- Ridge Vineyards (Acq 1986)
- Crystal Geyser Water Company (Acq 1990)
-
Astex Pharmaceuticals (Merged 2011, Acq 2013)
- Astex Therapeutics Limited
- SuperGen, Inc
- Avanir Pharmaceuticals (Acq 2014)
- Daiya (Acq 2017)
- ReCor Medical, Inc. (Acq 2019)
- Otsuka America, Inc
- Visterra (Acq 2019)
- Neurovance, Inc (Acq 2017)
- Mindset Pharma Inc (Acq 2023)
Products
